Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.

Johnson & Johnson's nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE).

An already-approved IV drug significantly reduces the symptoms of lupus, a new clinical trial showed. More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant ...

Louise Nelson was pregnant with her second child when her firstborn broke out in a bright red rash on his cheeks, a symptom of parvavirus. Doctors tested Louise and found antibodies to the virus, ...

Background Remission and low-disease activity are recommended targets in systemic lupus erythematosus (SLE), yet many ...

This explainer details common lupus warning signs and why early recognition matters for clinical assessment. It outlines lupus symptoms such as photosensitivity associated with rashes, low-grade fever ...

What Is Adquey, and Why Does It Matter? Adquey (difamilast 1%) is a prescription ointment the FDA has approved for adults and for children 2 and older who have mild to moderate atopic dermatitis (AD), ...

Lupus is a complex autoimmune disease that can affect any part of the body, and its symptoms often appear gradually, come and go, or look like those of other conditions. If you think you might have ...

dRheumatology Unit, Department of Medicine, University of Padua, Padua, Italy eDivision of Rheumatology, Department of Internal Medicine and Therapeutics, University of Pavia and Division of ...